It exploits a patented technology of penetrating and interfering peptides that penetrate inside the cell and specifically block certain protein-protein interactions, thus inhibiting key disease mechanisms.
PEP-010, its lead drug candidate derived from this technology, is a pro-apoptotic agent that has demonstrated anti-tumor efficacy in preclinical models, as well as a good safety profile. PEP-010 enters a phase Ia/b clinical trial for the treatment of advanced solid tumors, in partnership with the Institut Curie and Gustave Roussy, after obtaining authorization from the ANSM.
Original laboratory/Establishment: CIMI-Paris (Sorbonne University) and LIP (Preclinical Investigation Laboratory, Institut Curie)
Co-founder president of PEP-Therapy: Antoine PRESTAT;
Scientific co-founders: Angelita REBOLLO (UTCBS, Inserm/CNRS), Didier DECAUDIN (LIP, Institut Curie), Fariba NEMATI (LIP, Institut Curie)
